onc brain

Bladder

1 study across 1 date

2026-05-19

Bladder-preserving TMT for MIBC — prognostic factors for recurrence and survival (ESTRO 2026)

Multicenter Spanish TMT cohort (n=369 MIBC): CLR 63.7%; 5-FU-based CRT and image-guided RT predict response.

Bladder-preserving TMT for MIBC — prognostic factors for recurrence and survival (ESTRO 2026)
  • 📊 CLR 63.7%; disease progression 28.8% (local 10.1%, systemic 10.7%, combined 8.7%); salvage cystectomy 9.7%
  • 🔍 Multicenter retrospective cohort, Spain 2010-2022; 369 pts (median age 76, 85.1% male); cT2-T4aN0M0 treated with TURBT + concurrent chemoradiotherapy
  • 📐 Weekly portal imaging associated with lower CLR: OR 0.35 (95% CI 0.20-0.60), p<0.001
  • 📐 5-FU-based CRT associated with higher CLR: OR 4.9 (95% CI 1.1-22.1), p=0.038
  • 📊 VMAT showed trend toward favorable outcomes (not statistically significant)
  • 🔗 Authors report survival outcomes comparable to international series; supports TMT as standard alternative to RC in selected pts
  • ⚠️ Retrospective design; multicenter heterogeneity in CRT regimen, imaging, and era (2010-2022) limits internal validity
  • ⚠️ Primary endpoint CLR is a surrogate; OS and CSS data not quantified in source beyond qualitative comparison to international benchmarks
  • ⚠️ No randomised comparator vs radical cystectomy; selection bias for TMT candidates expected
📚 Sources · 🐦 1 tweet